![](/img/cover-not-exists.png)
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
Audrey Simon, Michel Peoch, Philippe Casassus, Eric Deconinck, Philippe Colombat, Bernard Desablens, Olivier Tournilhac, Houchingue Eghbali, Charles Foussard, Jerome Jaubert, Jean Pierre Vilque, JeanVolume:
151
Year:
2010
Language:
english
Pages:
8
DOI:
10.1111/j.1365-2141.2010.08329.x
File:
PDF, 237 KB
english, 2010